805316-72-7

Basic information

• Product Name: 1H-Imidazo[4,5-c]pyridin-7-amine,4,6-dichloro-1-methyl-(9CI)
• Synonyms: 1H-Imidazo[4,5-c]pyridin-7-amine,4,6-dichloro-1-methyl-(9CI);4,6-Dichloro-1-methyl-1H-imidazo[4,5-c]pyridin-7-amine
• CAS NO: 805316-72-7
• Molecular Formula: C₇H₆Cl₂N₄
• Molecular Weight: 217.058
• Product Categories: METHYL
• Mol File: 805316-72-7.mol

Chemical Properties

• Boiling Point: 459.5±55.0 °C(Predicted)
• Appearance: /
• Density: 1.76±0.1 g/cm3(Predicted)
• PKA: 3.56±0.30(Predicted)
• CAS DataBase Reference: 1H-Imidazo[4,5-c]pyridin-7-amine,4,6-dichloro-1-methyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Imidazo[4,5-c]pyridin-7-amine,4,6-dichloro-1-methyl-(9CI)(805316-72-7)
• EPA Substance Registry System: 1H-Imidazo[4,5-c]pyridin-7-amine,4,6-dichloro-1-methyl-(9CI)(805316-72-7)

Safety Data

• Hazardous Substances Data: 805316-72-7(Hazardous Substances Data)

Usage

Type of compound

Organic compound with pharmacological properties

Structure

Imidazo[4,5-c]pyridin-7-amine core with chloro and methyl substituents at positions 4 and 6

Applications

Useful in the pharmaceutical industry for various applications

Biological activities

Potential anti-tumor and anti-inflammatory properties

Synthesis

Used as a building block in the synthesis of pharmacologically active compounds

Upstream product

• 805316-71-6 2,6-dichloro-N'-methylpyridine-3,4,5-triamine 
• 122-51-0 orthoformic acid triethyl ester 
• 626-64-2 pyridin-4-ol 
• 19872-96-9 1H-3,5-dinitropyridine-4-one 
• 10425-70-4 4-chloro-3,5-dinitropyridine 
• 26820-38-2 (3,5-dinitropyridin-4-yl)methylamine 

Downstream Products

• 805316-73-8 N-(4,6-dichloro-1-methyl-1H-imidazole[4,5-c]pyridin-7-yl)-benzamide 
• 887254-61-7 1-benzoyl-3-(4,6-dichloro-1-methyl-1H-imidazo[4,5-c]pyridine-7-yl)thiourea 
• 887147-19-5 4,6-dichloro-1-methyl-1H-imidazo [4,5-c]pyridine 
• 887147-21-9 4-methylamino-6-chloro-1-methyl-1H-imidazo[4,5-c]pyridine 
• 914942-88-4 tert-butyl (6-amino-7-iodo-1-methyl-1H-imidazo[4,5-c]pyridin-4-yl)(methyl)carbamate 
• 914942-90-8 tert-butyl methyl(1-methyl-7-phenyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-4-yl)carbamate 
• 914942-89-5 tert-butyl 6-amino-1-methyl-7-(2-phenylethynyl)-1H-imidazo[4,5-c]pyridin-4-yl(methyl)carbamate 
• 914942-87-3 tert-butyl 6-(diphenylmethyleneamino)-1-methyl-1H-imidazo[4,5-c]pyridine-4-yl(methyl)carbamate 
• 914944-39-1 N-[[4-[1,6-dihydro-1-methyl-4-(methylamino)imidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl]phenyl]methyl]-acetamide 

Relevant articles and documents

Novel tricyclic inhibitors of 1κB kinase

The design and synthesis of a novel series of oxazole-, thiazole-, and imidazole-based inhibitors of IκB kinase (IKK) are reported. Biological activity was improved compared to the pyrazolopurine lead, and the expedient synthesis of the new tricyclic systems allowed for efficient exploration of structure-activity relationships. This, combined with an iterative rat cassette dosing strategy, was used to identify compounds with improved pharmacokinetic (PK) profiles to advance for in vivo evaluation.

8H-IMIDAZO[4,5-D]THIAZOLO[4,5-B]PYRIDINE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME

The present invention provides for thiazolopyridine-based tricyclic compounds having the formula (I) wherein R1, R2, R5 and R6 are as described herein. The present invention further provides pharmaceutical compo

Imidazo-fused oxazolo[4,5-b]pyridine and imidazo-fused thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same

The present invention provides for pyrazolopurine-based tricyclic compounds having the formula (I), wherein R1, R2, R3, and R6 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.

1, 6 -DIHYDRO- 1,3, 5, 6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AS INHIBITORS OF IKK ENZYME ACTIVITY

The present invention provides for tricyclic compounds having the formula (I) wherein R1, R2, R5, R6, R7, and R8 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.

IMIDAZO-FUSED OXAZOLO[4,5-B]PYRIDINE AND IMIDAZO-FUSED THIAZOLO[4,5-B]PYRIDINE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME

The present invention provides for pyrazolopurine-based tricyclic compounds having the formula (I),[chemical structure] wherein R1, R2, R3, R4, R5 and R6 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.